Utility of cerebrovascular imaging biomarkers to detect cerebral amyloidosis

INTRODUCTION The relationship between cerebrovascular disease (CVD) and amyloid beta (Aβ) in Alzheimer's disease (AD) is understudied. We hypothesized that magnetic resonance imaging (MRI)–based CVD biomarkers—including cerebral microbleeds (CMBs), lacunar infarction, and white matter hyperinte...

Full description

Saved in:
Bibliographic Details
Published in:Alzheimer's & dementia 2024-10, Vol.20 (10), p.7220-7231
Main Authors: Howe, Matthew D., Caruso, Megan R., Manoochehri, Masood, Kunicki, Zachary J., Emrani, Sheina, Rudolph, James L., Huey, Edward D., Salloway, Stephen P., Oh, Hwamee
Format: Article
Language:English
Subjects:
ADNI
Alzheimer's disease
amyloid beta
cerebrovascular disease
magnetic resonance imaging
positron emission tomography
small vessel disease
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:INTRODUCTION The relationship between cerebrovascular disease (CVD) and amyloid beta (Aβ) in Alzheimer's disease (AD) is understudied. We hypothesized that magnetic resonance imaging (MRI)–based CVD biomarkers—including cerebral microbleeds (CMBs), lacunar infarction, and white matter hyperintensities (WMHs)—would correlate with Aβ positivity on positron emission tomography (Aβ‐PET). METHODS We cross‐sectionally analyzed data from the Alzheimer's Disease Neuroimaging Initiative (ADNI, N = 1352). Logistic regression was used to calculate odds ratios (ORs), with Aβ‐PET positivity as the standard‐of‐truth. RESULTS Following adjustment, WMHs (OR = 1.25) and superficial CMBs (OR = 1.45) remained positively associated with Aβ‐PET positivity (p 
ISSN:1552-5260
1552-5279
1552-5279
DOI:10.1002/alz.14207